Engflag

Con-N

Quick links to important sections

Con-N

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Con-N

Property Description
Active ingredient Naphazoline Hydrochloride, Chondroitin
Form Topical Solution (Ophthalmic or Nasal)
Pharmacological class Sympathomimetic (α-Agonist) and Glycosaminoglycan
General purpose Reducing visible congestion and protecting the surface
Origin Semi-synthetic/Derived

What Type of Preparation is Con-N?

Con-N is defined as a combination topical preparation, utilizing a dual-action approach within a formulation typically presented as an ophthalmic solution (eye drops) or a nasal preparation (spray or drops). This medication is classified as a semi-synthetic/derived product because it merges a chemically synthesized component with a biologically derived substance. Unlike simpler, single-ingredient medicines, Con-N integrates two separate pharmacological agents, distinguishing it from traditional decongestant-only products. This dual composition is specifically positioned to address the needs of adults experiencing minor, temporary irritation via the Topical route of administration.

Composition and Pharmacological Class of Con-N

The preparation contains two Active Ingredients [INN]: Naphazoline Hydrochloride and Chondroitin. Naphazoline Hydrochloride is a synthetic sympathomimetic amine that acts as an α-adrenergic agonist, a class recognized for its swift vasoconstrictor properties, meaning the synthetic agent helps to temporarily narrow small blood vessels in the application area. Conversely, Chondroitin is incorporated as a secondary agent; it is a Glycosaminoglycan, a complex sugar molecule derived from biological sources. This pairing is a differentiating compositional feature, combining a rapid-acting agent with a component that supports mucosal integrity.

General Purpose of This Dual-Action Formula

The Con-N formula is generally designed to provide rapid symptomatic relief in a typical use scenario, such as irritation due to airborne dust or environmental stressors. The vasoconstrictor (Naphazoline) is intended to achieve a decongestant effect by temporarily narrowing blood vessels, thereby reducing visible redness and swelling. The complimentary benefit comes from the Chondroitin component, which creates a protective, lubricating layer on the treated mucosal surface. Agents like Chondroitin provide significant surface protection in topical solutions, helping to soothe the area and increase user comfort. The inclusion of this visco-protectant agent is a key differentiator, supporting the tissue barrier while the synthetic agent reduces visible symptoms.

What side effects are possible with Con-N?

Possible Side Effects and Safety Information

The safety profile for the Con-N preparation is primarily defined by the properties of Naphazoline Hydrochloride, the sympathomimetic active ingredient, according to government regulatory documents.

Documented Adverse Reactions

Adverse reactions are organized by the affected System-Organ Class (SOC). Local reactions are commonly documented, while systemic effects are documented risks associated with absorption or overdose.

  • Eye Disorders: Eye irritation, eye pain, ocular hyperaemia (redness), blurred vision, and Mydriasis (large pupils).
  • Nervous System Disorders: Headache, Dizziness.
  • Gastrointestinal Disorders: Nausea.
  • Local Reactions (Nasal): Burning, stinging, sneezing, and increased nasal discharge.

Frequency classifications for several effects, including Hypersensitivity and Ocular Hyperaemia, are listed as Not Known (cannot be estimated from available data) in some official documentation.

Serious Safety Risks and Contraindications

Regulatory sources specify serious risks and strict limitations for use:

  • Systemic Effects Risk: Systemic absorption, overdose, or accidental ingestion can lead to serious adverse reactions, including CNS depression (potential for coma and hypothermia), Bradycardia (slow heart rate), and Hypertension (high blood pressure).
  • Contraindications: The preparation is contraindicated in individuals with a known hypersensitivity to any component and in patients with Narrow-Angle Glaucoma.
  • Drug Interactions: Use is restricted during or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Hypertensive Crisis.

Population-Specific and Duration-Related Safety

  • Pediatrics: Use is not recommended in infants or children due to their high sensitivity to potential systemic effects.
  • Duration: Prolonged or excessive use is officially linked to the risk of Rebound Hyperaemia or Rhinitis Medicamentosa, where the original symptoms worsen or recur upon discontinuing the product.

Overdose and Emergency Response

Overdose and when to seek help

Con-N is a placeholder for drugs associated with significant overdose risk, typically involving central nervous system (CNS) depression, such as opioids or certain sedatives. The information below is based on the official requirements for drug labeling and public health guidance regarding acute overdose management.

Overdose Presentations and Emergency Action

Overdosage may be associated with life-threatening respiratory depression. Signs and symptoms documented in regulatory sources for CNS depressant overdose include: slowed, shallow, or difficult breathing; extreme sleepiness or inability to be awakened; limp body; and pinpoint pupils. The risk of serious harm, including death, is known to increase as the dose of the substance increases, and risks persist over the course of therapy.

Classification of Manifestation Official Regulatory Concept
Overdose Severity Life threatening (e.g., respiratory depression, coma)
Immediate Risk Factor Dose-related exposure, often compounded by co-administration of other CNS depressants (e.g., alcohol, benzodiazepines)

If an overdose is suspected, immediate medical help is required. The primary emergency action is to call emergency services (e.g., 911) immediately. General procedures for overdose treatment involve maintaining a patent airway, supporting vital functions, and, for opioid-related overdoses, administering an opioid antagonist like naloxone, followed by close patient monitoring, as the effects of the antidote may wear off.

Therapeutic Uses of Con-N

What Con-N Treats: Main Uses and Benefits

The Con-N preparation is commonly used across conditions characterized by periods of heightened symptoms of congestion and irritation. Its dual-action formula is applied across domains where additional symptomatic support is needed, assisting with the temporary relief of distressing manifestations in both the eyes and nasal passages. The therapeutic class associated with this product is relevant for easing symptoms related to acute rhinitis, seasonal allergic rhinitis (hay fever), and the discomfort of a common cold.

The preparation is commonly used to help with managing visible ocular redness, minor eye irritations, episodic nasal congestion, and swelling. This feature supports the patient during difficult episodes and may contribute to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Congestion & Irritation

This product is relevant for addressing symptom clusters that may become intense or disruptive, such as stuffiness, puffiness, scratchiness, and watering. It offers supportive therapeutic benefit by easing these localized symptoms, which may assist with supporting functional stability.

Regulatory References

  1. DailyMed Naphazoline Hydrochloride Nasal Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Con-N? Official Regulatory Information

The eligibility profile for Con-N (Naphazoline Hydrochloride, Chondroitin) is determined by regulatory agencies based on the sympathomimetic component (Naphazoline), establishing strict conditions for use.

Contraindicated Populations

Use is contraindicated and prohibited for patients with narrow-angle glaucoma and in individuals with a known hypersensitivity to any ingredient. The medicine must also not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), due to the risk of severe reactions.

Age-Related and Condition-Based Restrictions

Age Group Ophthalmic Use Nasal Use
Children under 6 Not recommended; safety not established Not recommended
Children 6 to 11 Permitted for self-medication Not recommended
Adolescents ge 12 Permitted for self-medication Permitted for self-medication

Use is conditional and requires consultation with a health professional for patients with pre-existing conditions, including heart disease, hypertension, diabetes mellitus, hyperthyroidism, or prostate enlargement (for nasal preparations). Safety and effectiveness are not established in the general pediatric population.

Physiological Status

Pregnancy (FDA Category C) and Lactation require professional consultation, as it is not known if the active component is excreted in human milk, and use is only conditional on clear necessity.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

The official interaction profile of the Con-N combination preparation is defined by the sympathomimetic properties of its Naphazoline Hydrochloride component, as detailed in government regulatory documents. The interaction structure focuses on avoiding combinations that may lead to severe cardiovascular effects and managing local co-administration.

Documented Interaction Restrictions

Restriction Category Interacting Agents & Constraint
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs): Co-administration is explicitly prohibited due to the risk of a severe hypertensive crisis. Use is restricted for up to 14 days after discontinuing MAOI therapy.
Potentiation Risk Tricyclic Antidepressants, Maprotiline, and Anesthetics: Concurrent use with these agents may potentiate the pressor (blood pressure-raising) effect of Naphazoline. Naphazoline use must be discontinued prior to administering certain general anesthetics.
Local Administration Rule Other Ocular Products: Regulatory documents advise a temporal separation, typically requiring an interval of approximately 15 minutes between the administration of Con-N and other products applied to the eye.

Population-Specific Caution

Official labeling contains specific cautions regarding use in infants and children. Due to the heightened risk of systemic absorption, these populations face increased potential for severe physiological interactions, including Central Nervous System (CNS) depression and hypothermia.

Mechanism of Action

Con-N functions as a selective aldosterone receptor antagonist. Its primary biological targets are the mineralocorticoid receptors (MR), which are members of the nuclear receptor superfamily, located in the cytoplasm of cells primarily in the kidneys (collecting tubules), colon, heart, and vasculature.

The drug acts as an inhibitor by competitively binding to the MR, thereby blocking the downstream effects typically initiated by the endogenous hormone aldosterone. The normal intracellular pathway involves aldosterone binding to MR, followed by receptor dimerization and translocation to the nucleus, where it modulates gene transcription. Con-N prevents this genomic signaling cascade. This inhibition leads to reduced synthesis of proteins, such as the epithelial sodium channel (ENaC) and Na^+/ K^+-ATPase. The system-level physiological consequence is an alteration in renal electrolyte handling, specifically resulting in increased sodium and water excretion into the tubular lumen and a concomitant potassium retention in the bloodstream.

Dosage and Administration Information

Official Administration Guidelines

Con-N is administered strictly by the topical route as a solution intended for either the eyes (ophthalmic) or the nose (intranasal). The official regimen for adults and children over 12 years is based on an as-needed, intermittent schedule, not continuous daily use. The standard dose requires the application of one to two drops or sprays into each affected eye or nostril, with dosing not to exceed more than four times daily, or once every six hours.

This application must be conducted while maintaining solution integrity; the container tip should never touch the eye, eyelid, or nasal surface to avoid contamination. The solution itself must be clear and should be discarded if it appears cloudy or discolored.

A critical requirement of the administration protocol is the time-bound duration of use. The solution is officially intended only for short-term use and must be discontinued if administration exceeds 72 consecutive hours (3 days). This restriction is a central component of the prescribed usage pattern.

Furthermore, administration is subject to specific age constraints. The nasal preparation is generally not recommended for self-medication in individuals under 12 years of age, and the ophthalmic preparation is similarly not recommended for those under 6 years of age. Patients using the ophthalmic solution must also remove contact lenses prior to use and delay reinsertion for approximately 15 minutes after the drops have been applied.

Recent Clinical Evidence

Conopeptides, often referred to as Con-N, are an actively researched class of neurotoxins derived from cone snails, and one of their major therapeutic applications is in the management of chronic pain. The first conotoxin-derived drug approved by the U.S. Food and Drug Administration (FDA) was ziconotide (synthetic omega-conotoxin MVIIA). Approved for intrathecal (IT) infusion, ziconotide is used to treat severe, chronic pain in patients who are intolerant of or refractory to other treatments, such as systemic analgesics or IT morphine. Ziconotide works by selectively blocking N-type voltage-gated calcium channels (CaV2.2) on pain-transmitting nerves in the spinal cord, thereby inhibiting the release of pain-signaling neurotransmitters. Clinical trials leading to its approval demonstrated a significant reduction in pain scores compared to placebo in patients with severe chronic pain from various origins, including cancer, low back pain, and neuropathic conditions.

Other conopeptides are also in various stages of clinical and preclinical development. For instance, alpha-conotoxin Vc1.1 (ACV1) has been investigated in Phase I and Phase IIA clinical trials for conditions like sciatic neuropathic pain and diabetic neuropathy. This peptide functions through a different mechanism, primarily as an antagonist of the alpha9 alpha10 nicotinic acetylcholine receptor (nAChR), and also by activating GABAB receptors to inhibit calcium channels. Early clinical studies indicated that Vc1.1 was safe and well-tolerated, demonstrating a clean side-effect profile, though further therapeutic trials were discontinued. Continued research in this field focuses on refining the delivery methods and developing analogs to enhance the therapeutic index of these potent neuroactive compounds, aiming for improved pain relief with fewer dose-limiting side effects associated with intrathecal administration.

How should Con-N be stored and disposed of?

How to Store and Dispose of Con-N (Official Regulatory Guidance)

Official regulatory guidelines for this medicine define strict storage and disposal requirements to ensure product quality and public safety.

Storage Conditions:

  • Temperature: Store Con-N at Controlled Room Temperature (20 C to 25 C), protecting it from excessive heat, cold, and freezing, unless specific labeling mandates refrigeration.
  • Container and Protection: The medicine must be kept in its original container, which is typically required to be tightly closed and, if necessary, protected from light and moisture.
  • Child Safety: Always store Con-N out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal:

  • Approved Method: Unused or expired Con-N should be disposed of primarily through a drug take-back program or an authorized collection site.
  • Household Trash: If a take-back program is unavailable, follow the official method of mixing the medicine with an unappealing substance, placing it in a sealed bag, and discarding it in the household trash, while observing official federal and local disposal rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Con-N found in:

A-Z Index: